Ionis-Novartis heart drug misses main goal of late-stage trial
04/09/2026 21:51
Ionis-Novartis heart drug misses main goal of late-stage trial Sept 4 (Reuters) - Ionis Pharmaceuticals IONS.O and partner Novartis' NOVN.S experimental drug to lower high levels of a type of fat and protein particle in heart patients, missed the main goal in a late-stage trial, the companies said on Friday.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)
Recent news on Novartis AG
See all newsNovartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant